moxifloxacin + isoniazid + rifampicin

This drug is a fixed-dose combination of three antibiotics—moxifloxacin, isoniazid, and rifampicin—used in the treatment of tuberculosis (TB). - **Moxifloxacin** is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and repair. - **Isoniazid** acts by inhibiting the synthesis of mycolic acids, vital components of the mycobacterial cell wall. - **Rifampicin** inhibits bacterial DNA-dependent RNA polymerase, suppressing RNA synthesis and leading to cell death. The combination targets *Mycobacterium tuberculosis* through multiple mechanisms to enhance bactericidal activity and reduce resistance emergence. This regimen may be considered in cases where there is resistance or intolerance to one component (e.g., isoniazid-resistant TB) or as part of efforts to shorten TB treatment duration[3][4][6]. Co-administration can result in pharmacokinetic interactions; notably, rifampicin reduces moxifloxacin exposure by inducing hepatic metabolism[4][6][7]. The combination has been studied for its efficacy in both drug-susceptible and certain drug-resistant forms of TB.